MAGE基因在肺癌疫苗研究进展  

Research progress of MAGE gene in lung cancer vaccine

作　　者：刘帮助[1] 刘超[1] 

机构地区：[1]蚌埠医学院第一附属医院呼吸内科,233004

出　　处：《国际呼吸杂志》2012年第4期317-320,共4页International Journal of Respiration

摘　　要：随着对肿瘤逃避免疫监视机制研究的不断深入，免疫治疗已成为一种有希望治疗肿瘤的新方法。其中肿瘤疫苗作为肿瘤的特异性主动免疫治疗成为肺癌非常有吸引力的靶向治疗策略之一，尤其适用于完全切除术后患者的辅助治疗。近年来肿瘤疫苗是采用MAGE多肽、基因和树突状细胞等方法来免疫肺癌患者，在Ⅰ／Ⅱ期临床试验中已观察到免疫反应和肿瘤的缓解，并取得了较好的临床疗效评价。目前正在进行国际多中心临床研究进行论证。As the tumor to evade immune surveillance mechanism for the continuous in-depth research, immunotherapy has become a promising new method for treatment of cancer. One cancer vaccine as a tumor-specific active immunotherapy of lung cancer becomes a very attractive strategy of targeted therapy, especially for patients with completely resected adjuvant therapy. In recent years, cancer vaccines is the use of MAGE peptides, genes, and dendritic cells in patients with lung cancer, tumor immune response and mitigation have been observed in phaseⅠ/linical trials, and good clinical evaluation achieved. Ongoing international multi-center clinical study will demonstrate it.

关 键 词：黑色素瘤抗原 免疫治疗 疫苗 肺癌 

分 类 号：R734.2[医药卫生—肿瘤]